Fosfomycin is named as an intervention in 3 current clinical trials in our Australia, China, Spain, Turkey, Singapore and Italy registers. 3 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is National University of Singapore (1). The most-studied condition is Bloodstream Infection. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Fosfomycin was first approved in Canada on 1 May 2019. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT07004049 · ClinicalTrials.gov ↗ · Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia
|
Phase 4 | Recruiting | National University of Singapore | China, Spain, Turkey, Singapore, Australia |
|
Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections
NCT05709028 · ClinicalTrials.gov ↗ · Urinary Tract Infections
|
Phase 3 | Recruiting | University of Sydney | Australia |
|
Use of Fosfomycin in the Treatment of Bacterial Infections
NCT06814899 · ClinicalTrials.gov ↗ · Analyze the Medical Records of Patients Admitted At ASST Lecco from 01/04/2020 to 31/12/2023 Treated with Fosfomycin IV
|
Observational | Recruiting | Azienda Ospedaliera di Lecco | Italy |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Fosfomycin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria
2026-525972-25-00 · Male Urogenital Diseases
|
Phase 3 | Authorised | Assistance Publique Hopitaux De Paris | France |
|
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
2026-526149-91-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Friedrich-Schiller-Universitaet Jena | Germany |
|
Multicentre, randomised, double-blind, placebo-controlled clinical trial to confirm the efficacy, safety, and clinical impact of the mucosal bacterial therapeutic vaccine MV140 in women with non-complicated recurrent urinary tract infections (rUTIs).
2025-524377-16-00 · CTIS ↗ · Bacterial Infections and Mycoses
|
Phase 3 | Authorised | Inmunotek S.L | Portugal |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Fosfomycin on the HPRA medicines list.
No entry for Fosfomycin in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| National University of Singapore | 1 |
| Azienda Ospedaliera di Lecco | 1 |
| University of Sydney | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Australia | 2 | 2 |
| Clinical trials in China | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Turkey | 1 | 1 |
| Clinical trials in Singapore | 1 | 1 |
| Clinical trials in Italy | 1 | 1 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
3 current trials in our Australia, China, Spain, Turkey, Singapore and Italy registers name Fosfomycin as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 2 with sites in Australia, 1 with sites in China, 1 with sites in Spain, 1 with sites in Turkey, 1 with sites in Singapore and 1 with sites in Italy. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
National University of Singapore (1), Azienda Ospedaliera di Lecco (1) and University of Sydney (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Fosfomycin, for example Fomicyt 40 mg/ml Powder for solution for infusion (InfectoPharm Arzneimittel und Consilium GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Fosfomycin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Fosfomycin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fosfomycin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fosfomycin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.